GW0742

$160

50g	100g	1kg
$670	$1255	$10900

Inquire Now Order

Description

GW 0742 – Product Information

GW 0742 is a PPARUβ/δ agonist that has been dubbed a “super cardarine”.

Studies have shown that GW 0742 improves blood glucose homeostasis and increases insulin sensitivity in diabetic rats. In diabetic rats fed a high fructose diet, the group that took GW 0742 had lower blood glucose compared to the control group.

Because GW 0742 is a PPAR agonist, it shows potential to increase fat loss by boosting metabolism and stimulating the utilization of fat as fuel.

This may increase muscle oxidative capacity, helping to burn more calories.

GW 0742 vs Cardarine

GW 0742 and Cardarine are PPAR (peroxisome proliferator-activated receptor) agonists.

Both drugs were originally developed by GlaxoSmithKline. Animal studies have shown that both drugs can improve insulin resistance in study subjects. They are also thought to potentially stimulate fatty acid oxidation (lower fatty acid levels) in animals.

However, there is one major difference between the two. GW 0742 contains two hydrogen and four fluorine atoms, while cardarine consists of one hydrogen and three fluorine atoms. That is, GW 0742 is a fluorinated analog of cardarine.

PureRawz sells GW 0742 and Cardarine for laboratory research.

GW 0742 and Metabolism

A study was conducted to investigate whether PPARβ/δ agonist treatment would improve exercise-induced immunometabolic changes in diet-induced obese mice. Results showed increased fatty acid oxidation gene expression and AMPK activity.

These effects were associated with decreased visceral adipose tissue mass (burning fat) and decreased skeletal muscle inflammation, as well as increased skeletal muscle oxidative capacity and insulin sensitivity.

GW 0742 and Insulin Resistance

Insulin resistance is an abnormal condition in which cells do not respond normally to insulin. Insulin resistance leads to increased insulin secretion in the body, which in turn leads to high blood pressure, atherosclerosis (hardening of the arteries), and increased triglyceride levels.

GW 0742 has been shown to improve metabolic abnormalities, including insulin resistance in skeletal muscle of mice fed a high fructose corn syrup diet. However, the effects of GW 0742 on systemic insulin sensitivity remain unexplained.

GW 0742 and inflammation

A study investigated the effects of GW 0742 on inflammation. The study found that the PPAR agonist reduced many parameters of inflammation and apoptosis (cell death). Overall, the results showed that GW 0742 reduced lung inflammation induced by bleomycin instillation in mice.

GW 0742 and diabetes

Animal experimental data showed that GW 0742 was able to improve glucose homeostasis (glucose uptake) in diabetic rats by activating PPAR-δ. Therefore, PPAR-δ is a good target for future development of anti-diabetic drugs.

GW 0742 and hypertension

A 2011 study aimed to investigate whether GW 0742 might exert antihypertensive effects in spontaneously hypertensive rats (SHR). GW 0742 induced a gradual decrease in systolic blood pressure and heart rate in SHR. Based on the results, the researchers proposed PPARβ as a new therapeutic target for hypertension.

Summary

GW 0742 is a PPAR receptor agonist that has demonstrated the potential to reduce inflammation, improve hypertension, and improve metabolic abnormalities in mice. However, due to the lack of human studies, its effects need further investigation.